Metropolis Healthcare Limited has informed the Exchange about Investor Presentation
METROPOLIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Metropolis Healthcare submitted its Q1FY26 investor presentation to the exchanges. On a group basis (including recent acquisitions), revenue rose 23% YoY to ₹386 Cr, EBITDA grew 14% YoY to ₹89 Cr (23.1% margin), and PAT increased 19% YoY to ₹45 Cr. On an organic basis, revenue grew 13% YoY to ₹355 Cr with EBITDA margin at 24.7%, improving sequentially due to better operating leverage. Patient volumes grew 7% YoY to 3.2 million and test volumes rose 8% YoY to 6.8 million. B2C revenue jumped 16% YoY and B2B grew 10% YoY despite pricing pressures. The company reaffirmed its 'Metropolis 3.0' strategy targeting mid-teen revenue CAGR from FY23 to FY26 and a return to pre-COVID margin profile, supported by 222 clinical labs and a network of 4,500+ service points across ~750 towns.
The presentation highlights healthy double-digit revenue growth, improving organic margins, and successful integration of three recent acquisitions (Core Diagnostics, DAPIC Dehradun, Scientific Pathology Agra). For shareholders, this signals continued operational momentum and reinforces confidence in the multi-year growth roadmap, though margins on the group level remain slightly below organic due to integration costs of newly acquired labs.